BR9912008A - Método de tratamento - Google Patents

Método de tratamento

Info

Publication number
BR9912008A
BR9912008A BR9912008-9A BR9912008A BR9912008A BR 9912008 A BR9912008 A BR 9912008A BR 9912008 A BR9912008 A BR 9912008A BR 9912008 A BR9912008 A BR 9912008A
Authority
BR
Brazil
Prior art keywords
treatment method
treatment
metroxiimino
azobicyclo
psychosis
Prior art date
Application number
BR9912008-9A
Other languages
English (en)
Inventor
Eve Naomi Cedar
James P Mccafferty
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of BR9912008A publication Critical patent/BR9912008A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Liquid Crystal Substances (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)

Abstract

"MéTODO DE TRATAMENTO" Uso da [R-(Z) ] -<244>- (metroxiimino) -<244>- (1-azobiciclo[2.2.2] oct-3-il) acetonitrila ou um sal farmaceuticamente compatível dela proveniente para o tratamento da psicose ou outros sintomas neuropsiquiátricos em pacientes com doença de Alzheimer com graves perturbações comportamentais.
BR9912008-9A 1998-07-15 1999-07-15 Método de tratamento BR9912008A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815383.6A GB9815383D0 (en) 1998-07-15 1998-07-15 Novel method of treatment
PCT/US1999/016002 WO2000003717A1 (en) 1998-07-15 1999-07-15 Method of treatment

Publications (1)

Publication Number Publication Date
BR9912008A true BR9912008A (pt) 2001-04-10

Family

ID=10835581

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912008-9A BR9912008A (pt) 1998-07-15 1999-07-15 Método de tratamento

Country Status (20)

Country Link
US (2) US20020156093A1 (pt)
EP (1) EP1104301B1 (pt)
JP (1) JP2002520364A (pt)
KR (1) KR20010071893A (pt)
CN (1) CN1146420C (pt)
AT (1) ATE444751T1 (pt)
AU (1) AU758936B2 (pt)
BR (1) BR9912008A (pt)
CA (1) CA2337229A1 (pt)
CZ (1) CZ2001150A3 (pt)
DE (1) DE69941509D1 (pt)
GB (1) GB9815383D0 (pt)
HU (1) HUP0103149A3 (pt)
IL (1) IL140629A0 (pt)
NO (1) NO20010195L (pt)
NZ (1) NZ509177A (pt)
PL (1) PL345505A1 (pt)
TR (1) TR200100088T2 (pt)
WO (1) WO2000003717A1 (pt)
ZA (1) ZA200100360B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008921D0 (en) * 2000-04-11 2000-05-31 Smithkline Beecham Plc Method of treatment
KR100971395B1 (ko) * 2003-07-23 2010-07-21 엘지디스플레이 주식회사 백 라이트 유닛
JP4792726B2 (ja) * 2003-10-30 2011-10-12 日亜化学工業株式会社 半導体素子用支持体の製造方法
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2219636T3 (es) * 1989-04-13 2004-12-01 Beecham Group P.L.C. Nuevos compuestos.
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
GB9615628D0 (en) * 1996-07-25 1996-09-04 Smithkline Beecham Plc Formulation
AU5716898A (en) * 1997-01-08 1998-08-03 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
AU7107998A (en) 1997-04-11 1998-11-11 Eli Lilly And Company Method for treating schizophrenia

Also Published As

Publication number Publication date
JP2002520364A (ja) 2002-07-09
WO2000003717A1 (en) 2000-01-27
ATE444751T1 (de) 2009-10-15
EP1104301A1 (en) 2001-06-06
CN1309564A (zh) 2001-08-22
KR20010071893A (ko) 2001-07-31
NO20010195D0 (no) 2001-01-12
US6750227B2 (en) 2004-06-15
EP1104301A4 (en) 2004-09-15
NO20010195L (no) 2001-01-12
CA2337229A1 (en) 2000-01-27
DE69941509D1 (de) 2009-11-19
AU758936B2 (en) 2003-04-03
CN1146420C (zh) 2004-04-21
HUP0103149A3 (en) 2003-03-28
CZ2001150A3 (cs) 2001-09-12
GB9815383D0 (en) 1998-09-16
US20020156093A1 (en) 2002-10-24
HUP0103149A2 (hu) 2002-01-28
IL140629A0 (en) 2002-02-10
ZA200100360B (en) 2002-03-12
PL345505A1 (en) 2001-12-17
NZ509177A (en) 2003-05-30
EP1104301B1 (en) 2009-10-07
AU5213799A (en) 2000-02-07
TR200100088T2 (tr) 2001-06-21
US20030125353A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
MY130145A (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders.
KR960700059A (ko) 파킨슨씨 병 및 파킨슨 중후군의 치료에 카르바마제핀 및 옥스카르바제핀의 이용(application of carbamazepine and oxcarbazepine in the treatment of parkinson&#39;s disease and parkinsonian syndromes)
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
PT2264018E (pt) Derivados de tioflavina para uso no diagnóstico da doença de alzheimer
ATE524176T1 (de) Valsartan tablette
BR9914940A (pt) Método para aperfeiçoar a farmacocinética de tipranavir
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
NZ332829A (en) Use of a polypeptide corresponding to a serine threonine kinase receptor, ALK-7 for neurological diseases
SI1553985T1 (sl) Bifenili kot sredstva za slikanje pri Alzheimerjevi bolezni
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
BR9912008A (pt) Método de tratamento
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
BR0011845A (pt) Complexo farmacêutico
WO2001045685A3 (en) Formulations of adenosine a1 agonists
TNSN04101A1 (fr) ASSOCIATIONS PHARMACEUTIQUES D&#39;UN AGONISTE DE RECEPTEUR D&#39;ADENOSINE A2a ET D&#39;UN AGONISTE DE RECEPTEUR ADRENERGIQUE B2
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
WO2001045682A3 (en) Formulations of adenosine a1 agonists

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1922 DE 06/11/2007.